Fortrea Holdings (MEX:FTRE1) EBIT: MXN-6,754 Mil (TTM As of Mar. 2026)


MEX:FTRE1 Fortrea Holdings Inc MEX:FTRE1
66 GF Score
Price MXN435.30
GF Value MXN448.82
! 7 Warning Signs
View Full Analysis

What is Fortrea Holdings EBIT?

Fortrea Holdings MEX:FTRE1 66 EBIT is MXN-6,754 Mil as of Mar. 2026. GuruFocus rates MEX:FTRE1 with a GF Score™ of 66/100 and a GF Value™ of MXN448.82. The stock has 7 warning signs investors should review.

Fortrea Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was MXN123 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-6,754 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fortrea Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was 0.55%. Fortrea Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 17.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fortrea Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -14.60%.


Fortrea Holdings  (MEX:FTRE1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Fortrea Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=238.032 * ( 1 - 0% )/( (44567.709 + 41527.505)/ 2 )
=238.032/43047.607
=0.55 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=48898.08 - 4620.263 - ( 3143.795 - max(0, 16444.606 - 16154.714+3143.795))
=44567.709

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=48388.947 - 7719.799 - ( 2659.823 - max(0, 16754.182 - 15895.825+2659.823))
=41527.505

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Fortrea Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=490.488/( ( (2691.852 + max(-12299.693, 0)) + (2832.937 + max(-12009.779, 0)) )/ 2 )
=490.488/( ( 2691.852 + 2832.937 )/ 2 )
=490.488/2762.3945
=17.76 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2045.448 + 0 + 1847.385) - (4620.263 + 8531.101 + 3041.162)
=-12299.693

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2326.218 + 0 + 2062.941) - (7719.799 + 8679.139 + 0)
=-12009.779

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Fortrea Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-6753.813/46246.945
=-14.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortrea Holdings EBIT Related Terms


Fortrea Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Fortrea Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortrea Holdings EBIT Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 2,802.21 3,649.65 665.39 -3,153.38 -16,053.88

Fortrea Holdings Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10,754.88 -6,541.26 -111.90 -223.27 122.62

MEX:FTRE1 vs MAZE, KALV, BCAX: EBIT Comparison

For the Biotechnology subindustry, Fortrea Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortrea Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's EV-to-EBIT falls into.


MEX:FTRE1
66GF Score
Fortrea Holdings Inc MEX:FTRE1
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortrea Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-6,754 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of MXN-6,754 Mil mean?
Fortrea Holdings (MEX:FTRE1) has a EBIT of MXN-6,754 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Fortrea Holdings.
Is Fortrea Holdings' EBIT too high?
Fortrea Holdings' current EBIT is MXN-6,754 Mil. Overall, Fortrea Holdings has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' EBIT compare to MAZE and KALV?
Fortrea Holdings' EBIT of MXN-6,754 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Fortrea Holdings. Fortrea Holdings's current EBIT is MXN-6,754 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Fortrea Holdings (MEX:FTRE1) has a current EBIT of MXN-6,754 Mil. The stock's GF Value™ is MXN448.82, compared to a current price of MXN435.30 — trading 3% below its estimated fair value. The current EBIT is MXN-6,754 Mil. Fortrea Holdings' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Fortrea Holdings (MEX:FTRE1), the current EBIT is MXN-6,754 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortrea Holdings (MEX:FTRE1) Overvalued in 2026?

Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued. The current stock price of MXN435.30 is trading 3% below its estimated GF Value™ of MXN448.82.

Key valuation signals for MEX:FTRE1:

  • EBIT: MXN-6,754 Mil
  • GF Value™: MXN448.82 vs. price of MXN435.30 (3% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the MEX:FTRE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fortrea Holdings Business Description

Other Exchanges FTRE:USAK67:Germany
Address 8 Moore Drive, Durham, NC, USA, 27713
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
66GF Score

Get the complete analysis for MEX:FTRE1

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN435.30
Price
MXN448.82
GF Value